Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Peer

Showing results (61-70 of 181) with videos related to

Pageof 19
Sort By:
Cancer Metastasis Reviews|May 8, 2015
Nanomedicine as an emerging platform for metastatic lung cancer therapyDalit Landesman-Milo, Srinivas Ramishetti, Dan Peer
Journal of Drug Targeting|April 1, 2016
Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticlesSrinivas Ramishetti, Dalit Landesman-Milo, Dan Peer
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 28, 2016
ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cellsNeta Soffer-Tsur, Dan Peer, Tal Dvir
Expert Opinion on Drug Delivery|September 17, 2014
Overcoming multidrug resistance with nanomedicinesAssaf Ganoth, Keren Cohen Merimi, Dan Peer
Expert Opinion on Drug Delivery|June 14, 2016
Harnessing nanomedicine for therapeutic intervention in glioblastomaAnna Gutkin, Zvi R Cohen, Dan Peer
Cancer Letters|September 1, 2014
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicineVelthe Drinberg, Rivka Bitcover, Wolf Rajchenbach, et al.
Journal of Drug Targeting|October 9, 2018
Targeting central nervous system pathologies with nanomedicinesShoshy Mizrahy, Anna Gutkin, Paolo Decuzzi, et al.
Cancer Research|October 20, 2004
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor modelsDan Peer, Yaron Dekel, Dina Melikhov, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 18, 2022
Delivery strategies of RNA therapeutics to leukocytesDana Tarab-Ravski, Lior Stotsky-Oterin, Dan Peer
Cancer Letters|October 15, 2008
Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimenMirit Argov, Rina Kashi, Dan Peer, et al.
Pageof 19

Showing results (61-70 of 181) with videos related to

Sort By:
Pageof 19
Cancer Metastasis Reviews|May 8, 2015
Nanomedicine as an emerging platform for metastatic lung cancer therapyDalit Landesman-Milo, Srinivas Ramishetti, Dan Peer
Journal of Drug Targeting|April 1, 2016
Advances in RNAi therapeutic delivery to leukocytes using lipid nanoparticlesSrinivas Ramishetti, Dalit Landesman-Milo, Dan Peer
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 28, 2016
ECM-based macroporous sponges release essential factors to support the growth of hematopoietic cellsNeta Soffer-Tsur, Dan Peer, Tal Dvir
Expert Opinion on Drug Delivery|September 17, 2014
Overcoming multidrug resistance with nanomedicinesAssaf Ganoth, Keren Cohen Merimi, Dan Peer
Expert Opinion on Drug Delivery|June 14, 2016
Harnessing nanomedicine for therapeutic intervention in glioblastomaAnna Gutkin, Zvi R Cohen, Dan Peer
Cancer Letters|September 1, 2014
Modulating cancer multidrug resistance by sertraline in combination with a nanomedicineVelthe Drinberg, Rivka Bitcover, Wolf Rajchenbach, et al.
Journal of Drug Targeting|October 9, 2018
Targeting central nervous system pathologies with nanomedicinesShoshy Mizrahy, Anna Gutkin, Paolo Decuzzi, et al.
Cancer Research|October 20, 2004
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor modelsDan Peer, Yaron Dekel, Dina Melikhov, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|January 18, 2022
Delivery strategies of RNA therapeutics to leukocytesDana Tarab-Ravski, Lior Stotsky-Oterin, Dan Peer
Cancer Letters|October 15, 2008
Treatment of resistant human colon cancer xenografts by a fluoxetine-doxorubicin combination enhances therapeutic responses comparable to an aggressive bevacizumab regimenMirit Argov, Rina Kashi, Dan Peer, et al.
Pageof 19